Sophia Genetics SA (ticker: SOPH) listed its shares on the Nasdaq in July 2021. Sophia Genetics is a health care technology company dedicated to establishing the practice of data driven medicine as the standard of care and for life science research. Sophia Genetics raised gross proceeds of USD 234 million in its IPO.
Tavernier Tschanz advised Sophia Genetics on corporate law matters and shareholders matter in this transaction. Tavernier Tschanz was also involved in connection with Sophia Genetics’ equity incentive plans and related tax matters.